Balyasny Asset Management
HBIO icon

Balyasny Asset Management’s Harvard Bioscience HBIO Stock Holding History

Balyasny Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,151
Closed -$55K – 2954
2022
Q3 		$55K Buy
+2,151
New +$71.2K ﹤0.01% 2470
2016
Q1 		– Sell
-3,516
Closed -$122K – 1366
2015
Q4 		$122K Buy
3,516
+2,011
+134% +$68.8K ﹤0.01% 1152
2015
Q3 		$57K Sell
1,505
-39
-3% -$1.81K ﹤0.01% 1088
2015
Q2 		$88K Buy
1,544
+146
+10% +$8.31K ﹤0.01% 1080
2015
Q1 		$81K Buy
+1,398
New +$75.1K ﹤0.01% 900

Other funds holding HBIO

2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Balyasny Asset Management's HBIO Position: Q4 2022 in Review

Balyasny Asset Management sold out of Harvard Bioscience (HBIO) in Q4 2022, closing a stake of 2,151 shares — an estimated $55K sold.

Balyasny Asset Management first reported a position in HBIO in Q1 2015 and held it in 5 quarters. The position peaked at $122K in Q4 2015. 68 funds tracked by Wall St. Rank hold HBIO as of Q4 2022.

  • Balyasny Asset Management reported no remaining Harvard Bioscience position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 2,151 Harvard Bioscience shares in Q4 2022, an estimated $55K.
  • Balyasny Asset Management first reported a position in Harvard Bioscience in Q1 2015 and held it in 5 quarters.
  • Balyasny Asset Management's Harvard Bioscience position peaked at $122K in Q4 2015.
  • 68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.